Skip to content
10-Q

Quarterly Report

Astria Therapeutics, Inc.

0001410578-24-001933

← back to feed
Filed
Nov 13, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2024 · Oct 31, 2024 56.43M sh
Short Term Investments Q3 2024 · Sep 30, 2024 $263.38M
Short Term Investments Q3 2024 · Dec 31, 2023 $71M
Cash And Equivalents Q3 2024 · Sep 30, 2024 $80.9M
Cash And Equivalents Q3 2024 · Dec 31, 2023 $175.53M
Cash And Equivalents Q3 2024 · Sep 30, 2023 $119.81M
Current Liabilities Q3 2024 · Sep 30, 2024 $15.72M
Current Liabilities Q3 2024 · Dec 31, 2023 $11.55M
Total Liabilities Q3 2024 · Sep 30, 2024 $19.99M
Total Liabilities Q3 2024 · Dec 31, 2023 $11.55M
Current Assets Q3 2024 · Sep 30, 2024 $351.86M
Current Assets Q3 2024 · Dec 31, 2023 $250.94M
Total Assets Q3 2024 · Sep 30, 2024 $361.64M
Total Assets Q3 2024 · Dec 31, 2023 $254.67M
Shares Diluted Q3 2024 · Sep 30, 2023 28.04M sh
Shares Diluted Q3 2024 · Sep 30, 2023 28M sh
Capex Q3 2024 · Sep 30, 2023 $9K
Operating Cash Flow Q3 2024 · Sep 30, 2023 −$38.21M
Stockholders Equity Q3 2024 · Sep 30, 2023 $184.48M
Stockholders Equity Q3 2024 · Jun 30, 2023 $200.4M
Stockholders Equity Q3 2024 · Mar 31, 2023 $211.36M
Stockholders Equity Q3 2024 · Dec 31, 2022 $221.22M
Eps Diluted Q3 2024 · Sep 30, 2023 −$0.63
Eps Diluted Q3 2024 · Sep 30, 2023 −$1.48
Eps Basic Q3 2024 · Sep 30, 2023 −$0.63
Eps Basic Q3 2024 · Sep 30, 2023 −$1.48
Sga Expense Q3 2024 · Sep 30, 2023 $6.9M
Sga Expense Q3 2024 · Sep 30, 2023 $18.37M
Net Income Q3 2024 · Sep 30, 2023 −$17.73M
Net Income Q3 2024 · Sep 30, 2023 −$41.48M
Net Income Q3 2024 · Jun 30, 2023 −$12.57M
Net Income Q3 2024 · Mar 31, 2023 −$11.19M
Operating Income Q3 2024 · Sep 30, 2023 −$20.24M
Operating Income Q3 2024 · Sep 30, 2023 −$48.83M